Closed System Transfer Devices Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)

Closed System Transfer Devices Market Growth Factors

Technological Advancements Are a Key Market Trend

• Technological advancements in closed-system transfer devices, such as the introduction of needle-free systems, membrane-to-membrane technology, and capability to integrate with digital health technologies, are a key market trend.
• Needle-free CSTDs help reduce the risk of needlestick injuries, which is a concern for healthcare staff working with cytotoxic drugs and infection control.
• Additionally, the integration of the membrane-to-membrane technology offers a higher level of safety during the drug transfer process.
• Further, the membrane-to-membrane technology complies with safety standards, such as the USP<800>, and used in various hazardous environments, such as chemotherapy and antiviral medications.
• The development of advanced material for CATDs has significantly improved their safety, efficiency, and usability, as these materials are lightweight and strong.
• In October 2023, Equashield launched the EQUASHIELD Syringe Unit, which has received FDA clearance for full-volume use.
• The syringe units use advanced materials, which help in ensuring a leak-proof connection.

Increasing Demand for Chemotherapy among Cancer Patients Is Key Market Driver

• The rising global cases of cancer drive the demand for chemotherapy, which uses toxic and hazardous drugs.
• This creates a demand for advanced closed-system transfer devices for efficient drug delivery.
• According to the World Health Organization cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths every year.
• Infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries.
• With the surging cases of cancer, the demand for curing drugs is also rising.
• Healthcare workers can get exposed to these drugs through accidental hand-to-mouth ingestion, skin contact, inhalation, and needle stick or sharps injuries.
• This can cause reproductive reactions (including infertility and congenital malformations), skin rashes, leukemia, fetal malformation, and impact bone marrow.
• Thus, the National Institute for Occupational Safety and Health (NIOSH) has recommended the use of closed-system transfer devices (CSTDs) to eliminate the risk of these harmful reactions.

High Initial Cost Is Key Market Challenge

• The high initial cost associated with closed-system transfer devices is a key challenge in the market growth.
• The initial cost includes upfront capital investment, additional cost for the infrastructure and training, maintenance, and replacement, which further acts as a major challenge for small healthcare facilities in adopting them.
• Furthermore, maintenance and replacement cost associated with CSTDs is very high as it requires regular maintenance to ensure their proper functioning.
• Moreover, the additional expenses required for the infrastructure and training further adds up to the cost associated to the CSTDs.
• In India, every cycle of chemotherapy can cost up to INR 50,000, which restrict lower-and-middle-income patients or those without coverage to get it.

Closed System Transfer Devices Market Segmentation Analysis

Type Analysis

Based on type, the membrane-to-membrane category accounted for a larger revenue share, of 60%, in 2024, and it is expected to witness the same trend during the forecasted period as well. This is due to the ease of usage of these membranes and the less chance of contamination in these double-membrane devices. Also, the volume loss in this category is very less as compared to needleless. Some products that are being offered in this category by companies are the OnGuard Tevadaptor device, PhaSeal, Halo, Equashield I and II, and the SureConnect products.

On the other hand, the needleless category is expected to grow at a higher rate in the coming years. This can be due to the increasing advantage of using needleless devices such as needle-free transfer of medication and the surging product launches by key players in the industry. Some examples are ChemoClave, ChemoLock, SureConnect, Vialshield, and Texium.

Based on type, the market has the following categories:

• Membrane-to-Membrane (Larger Category)
• Needleless (Faster-Growing Category)

Technology Insights

The diaphragm technology held the largest market share, of 45%, in 2024. The flexible of these CSTDs acts as an effective barrier against contamination, which reduces the risk of exposure to healthcare professionals. Diaphragm-based CSTDs are relatively simple in design compared to other advanced CSTDs, which makes them a popular option among healthcare institutions. Furthermore, diaphragm-based CSTDs have been widely adopted for handling chemotherapy drugs, which are highly toxic and require strict handling process.

The air cleaning/filtration technology will grow at the highest CAGR of 12.9%, during the forecast period. This growth can be attributed to the rising demand for comprehensive safety solutions to address multiple exposure risks, which include both liquid and airborne hazardous drugs.

Based on technology, the market has the following categories:

• Diaphragm-based (Largest Category)
• Compartmentalized
• Air Cleaning/Filtration (Fastest-Growing Category)

Closing Mechanism Analysis

The Luer lock system category held the largest market share, of 40%, in 2024 as it provides high reliable and secure connection for medical devices. Its threaded locking mechanism ensures a secure and tight fit, which prevents accidental disconnection during drug transfer. Additionally, this system is compatible with a wide range of medical devices, including syringes, vials, and infusion pumps, which drives it sales to hospitals, clinics, and pharmacies.

The click-to-lock system will grow at the highest CAGR, of 12.8%, during the forecast period, attributed to technological advancement and the need for an enhanced user experience. The demand for this closing mechanism is rising for handling high-risk drugs, such as chemotherapy agents. The audible lock used in this system ensures that the system is locked securely, reducing the human error.

Based on closing mechanism, the market has the following categories:

• Push-to-lock Systems
• Click-to-lock Systems (Fastest-Growing Category)
• Luer Lock Systems (Largest Category)
• Color-to-color alignment System

Component Analysis

Based on component, the vial access category accounted for the largest share in 2024. This is due to the increasing usage of these devices by nurses for the transfer of hazardous drugs such as antineoplastic drugs from vials into the infusion chamber of the patient. It is a pressure equalization system, applying a closed expansion chamber that creates and keeps neutral pressure when diluent or air is inoculated into or enunciated from the vial.

The bag/line access device category will grow at the highest CAGR, of 13.1%, during the forecast period. The growth can be attributed to their rise in use in oncology treatments to provide safe, efficient, and secure drug transfer. Additionally, technological advancements, such as one-handed operation, easier attachment, and better sealing mechanism, drive the growth of the category.

Based on component, the market has the following categories:

• Vial Access Devices (Largest Category)
• Syringe Safety Devices
• Bag/line Access Devices (Fastest-Growing Category)
• Accessories

End User Analysis

On the basis of end user, the hospitals & clinics category holds the larger revenue share. This is attributed to the huge population base of cancer patients, who are being cured and handled by a large number of hospitals and clinics. Due to a large number of cancer cases and healthcare facilities, the number of healthcare workers who are working directly in contact with hazardous drugs is very high.

Moreover, the high purchasing power of hospitals is making them the biggest end users of these high-priced devices. Also, hospitals and clinics have to comply with all regulatory guidelines that are being given by regulatory bodies. Thus, these factors drive the demand for CSTDs in this category.

The oncology centers category will grow at the higher CAGR, of 13.5%, during the forecast period, due to the rise in the number of these centers and increasing number of cancer cases. These places specialize in chemotherapy, which uses hazardous drugs containing cytotoxic agents. This creates a requirement for modern CSTDs for handling these drugs.

Based on end user, the market has the following categories:

• Hospitals & Clinics (Larger Category)
• Oncology Centers (Faster-Growing Category)

Closed System Transfer Devices Market Regional Outlook

In 2024, North America accounted for the largest market share of 45%, due to the increasing awareness of healthcare workers toward hazardous drugs and their effects, and the presence of major players who are manufacturing these devices in the region. In North America, the U.S. holds a larger revenue share, owing to the large number of cancer cases in the country. For instance, according to the American Cancer Society, there were around 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S.

On the other hand, the APAC market will witness the fastest growth with the highest CAGR of 13.5%, during the forecast period. This can be ascribed to the rising number of cancer cases in the region. Cancer is the second-leading cause of death after cardiovascular diseases in APAC. Also, the region accounts for 50% of the world’s new cancer cases each year. In addition, due to the increasing healthcare investments and demand for better services, major players are focusing on the region for increasing the sales of CSTDs.

According to the National Institute of Health, the number of cancer cases in India in 2022 was 1,461,427 (with a crude incidence rate of 100.4 per 100,000 population). A higher number of cases in females (749,251 cases, 105.4 per 100,000) was seen compared to males (712,176 cases, 95.6 per 100,000). It is estimated that the number of cancer cases will increase by 12.8% in 2025 compared to 2020.

Based on geography, the market has the following categories:

• North America (Largest-Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Faster-Growing Country Market)
• Europe
  • Germany (Largest Country Market)
  • U.K.
  • France
  • Italy
  • Spain (Faster-Growing Country Market)
• Asia-Pacific (Fastest-Growing Regional Market)
  • Japan (Largest Country Market)
  • China
  • India (Fastest-Growing Country Market)
  • South Korea
  • Australia
• Latin America
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa
  • Saudi Arabia (Largest Country Market)
  • South Africa
  • U.A.E. (Fastest-Growing Country Market)

Closed System Transfer Devices Market Share

• The market for global CSTDs is moderately fragmented with the diverse range of manufacturers.
• They include ICU Medical, B.Braun Melsungen AG, BD, Corvida Medical, and Yukon Medical.
• Various organizations and associations are working to improve global health standards, to ensure the quality, safety, and benefit of medicines.
• The United States Pharmacopeia (USP) is one of them, which has described the practices and standards for handling hazardous drugs.
• It works to promote patient safety, worker safety, and environmental protection through the use of closed-system transfer devices.

Closed System Transfer Devices Market News & Updates

• In April 2025, Simplivia Healthcare Ltd. exhibited its Chemfort CTSD and SmartCompounders automated solution at ISOPP CAPhO 2025 Symposium, ahead of their scheduled launch in Canada.
• In December 2024, EQUASHIELD entered into a partnership with Pharmacy Stars, which provides a cloud-based platform for pharmacy compliance to enhance safety across healthcare systems.
• In November 2024, Zephyrus Innovations introduced the VaporShield CSTD at the PODD Conference in Boston, MA.
• In January 2022, ICU Medical Inc. acquired Smiths Medical from Smiths Group plc.